{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:47Z","timestamp":1792815227629,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002943","name":"Departament d'Innovaci\u00f3, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["PERIS SLT00433"],"award-info":[{"award-number":["PERIS SLT00433"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002943","name":"Departament d'Innovaci\u00f3, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SGR 01139 2021"],"award-info":[{"award-number":["SGR 01139 2021"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01246"],"award-info":[{"award-number":["PI17\/01246"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01621"],"award-info":[{"award-number":["PI20\/01621"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01205-5","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:29:17Z","timestamp":1736591357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-2371","authenticated-orcid":false,"given":"Guadalupe","family":"O\u00f1ate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-1649","authenticated-orcid":false,"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diaz-Beya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7465-6203","authenticated-orcid":false,"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-0025","authenticated-orcid":false,"given":"Olga","family":"Salamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Vall-Llovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcia-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francisca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-346X","authenticated-orcid":false,"given":"Josep F.","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0356","authenticated-orcid":false,"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt AS, Hagberg O, H\u00f6glund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890\u20139.","journal-title":"Blood"},{"key":"1205_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/0284186X.2015.1115124","volume":"55","author":"LF Ocias","year":"2016","unstructured":"Ocias LF, Larsen TS, Vestergaard H, Friis LS, Abildgaard N, Frederiksen H, et al. Trends in hematological cancer in the elderly in Denmark, 1980-2012. Acta Oncol. 2016;55:98\u2013107.","journal-title":"Acta Oncol"},{"key":"1205_CR5","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48:3257\u201366.","journal-title":"Eur J Cancer"},{"key":"1205_CR6","first-page":"1513","volume":"91","author":"B Deschler","year":"2006","unstructured":"Deschler B, de Witte T, Mertelsmann R, L\u00fcbbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91:1513\u201322.","journal-title":"Haematologica"},{"key":"1205_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood.2020005524","volume":"137","author":"L Fenwarth","year":"2021","unstructured":"Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis JH, Lesieur A, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021;137:524\u201332.","journal-title":"Blood"},{"key":"1205_CR8","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3324\/haematol.13309","volume":"93","author":"JV Malfuson","year":"2008","unstructured":"Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806\u201313.","journal-title":"Haematologica"},{"key":"1205_CR9","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417\u201323.","journal-title":"J Clin Oncol"},{"key":"1205_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","volume":"97","author":"B Oran","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916\u201324.","journal-title":"Haematologica"},{"key":"1205_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997\u20139.","journal-title":"Leukemia"},{"key":"1205_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Dohner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"1205_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00555-8","volume":"11","author":"AH Wei","year":"2021","unstructured":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141\/150). Blood Cancer J. 2021;11:163.","journal-title":"Blood Cancer J"},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","volume":"7","author":"NJ Short","year":"2023","unstructured":"Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, et al. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023;7:3573\u201381.","journal-title":"Blood Adv"},{"key":"1205_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023;98:1254\u201364.","journal-title":"Am J Hematol"},{"key":"1205_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transpl. 2022;57:160\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1205_CR17","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.20.01788","volume":"38","author":"G Ossenkoppele","year":"2020","unstructured":"Ossenkoppele G, Vyas P. BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML. J Clin Oncol. 2020;38:3461\u20134.","journal-title":"J Clin Oncol"},{"key":"1205_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"1205_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl J Med. 1994;331:896\u2013903.","journal-title":"N. Engl J Med"},{"key":"1205_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453\u201374.","journal-title":"Blood"},{"key":"1205_CR21","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"1205_CR22","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121:2734\u20138.","journal-title":"Blood"},{"key":"1205_CR23","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","volume":"6","author":"A Bataller","year":"2022","unstructured":"Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6:1193\u2013206.","journal-title":"Blood Adv"},{"key":"1205_CR24","doi-asserted-by":"crossref","unstructured":"Bataller A, Onate G, Diaz-Beya M, Guijarro F, Garrido A, Vives S, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol 2020.","DOI":"10.1111\/bjh.16857"},{"key":"1205_CR25","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"1205_CR26","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell Jr","year":"1982","unstructured":"Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543\u20136.","journal-title":"JAMA"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"1205_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508\u201316.","journal-title":"Lancet"},{"key":"1205_CR29","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239\u201346.","journal-title":"Blood"},{"key":"1205_CR30","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021;39:2768\u201378.","journal-title":"J Clin Oncol"},{"key":"1205_CR31","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565\u201373.","journal-title":"Blood Adv"},{"key":"1205_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1205_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjh.17185","volume":"193","author":"R Dillon","year":"2021","unstructured":"Dillon R, Potter N, Freeman S, Russell N. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Br J Haematol. 2021;193:231\u201344.","journal-title":"Br J Haematol"},{"key":"1205_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1205_CR35","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:1890\u20139.","journal-title":"JAMA Oncol"},{"key":"1205_CR36","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143:1931\u20136.","journal-title":"Blood"},{"key":"1205_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00839-1","volume":"13","author":"G Onate","year":"2023","unstructured":"Onate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, et al. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J. 2023;13:69.","journal-title":"Blood Cancer J"},{"key":"1205_CR38","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl J Med. 2016;374:2209\u201321.","journal-title":"N. Engl J Med"},{"key":"1205_CR39","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.13912","volume":"172","author":"JM Middeke","year":"2016","unstructured":"Middeke JM, Herold S, Rucker-Braun E, Berdel WE, Stelljes M, Kaufmann M, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172:914\u201322.","journal-title":"Br J Haematol"},{"key":"1205_CR40","doi-asserted-by":"crossref","unstructured":"Zhao D, Zarif M, Zhou Q, Capo-Chichi JM, Schuh A, Minden MD, et al. TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation. Cancers (Basel) 2023;15.","DOI":"10.3390\/cancers15123210"},{"key":"1205_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","volume":"8","author":"MT Nawas","year":"2024","unstructured":"Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML. Blood Adv. 2024;8:553\u201361.","journal-title":"Blood Adv"},{"key":"1205_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","volume":"37","author":"T Badar","year":"2023","unstructured":"Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023;37:799\u2013806.","journal-title":"Leukemia"},{"key":"1205_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12983-z","volume":"10","author":"F Caiado","year":"2019","unstructured":"Caiado F, Maia-Silva D, Jardim C, Schmolka N, Carvalho T, Reforco C, et al. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nat Commun. 2019;10:4986.","journal-title":"Nat Commun"},{"key":"1205_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/21556660.2018.1492925","volume":"7","author":"UH Acharya","year":"2018","unstructured":"Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, et al. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018;7:51\u201353.","journal-title":"J Drug Assess"},{"key":"1205_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102549","volume":"71","author":"MS Linet","year":"2024","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019. EClinicalMedicine. 2024;71:102549.","journal-title":"EClinicalMedicine"},{"key":"1205_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41375-023-02068-8","volume":"38","author":"M Ozga","year":"2024","unstructured":"Ozga M, Nicolet D, Mrozek K, Yilmaz AS, Kohlschmidt J, Larkin KT, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38:45\u201357.","journal-title":"Leukemia"},{"key":"1205_CR47","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","volume":"3","author":"ML Sorror","year":"2017","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017;3:1675\u201382.","journal-title":"JAMA Oncol"},{"key":"1205_CR48","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.20.01392","volume":"38","author":"R Palmieri","year":"2020","unstructured":"Palmieri R, Othus M, Halpern AB, Percival MM, Godwin CD, Becker PS, et al. Accuracy of SIE\/SIES\/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. J Clin Oncol. 2020;38:4163\u201374.","journal-title":"J Clin Oncol"},{"key":"1205_CR49","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41375-022-01677-z","volume":"36","author":"C Desprez","year":"2022","unstructured":"Desprez C, Riou J, Peterlin P, Marchand T, Couturier MA, Villate A, et al. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study. Leukemia. 2022;36:2408\u201317.","journal-title":"Leukemia"},{"key":"1205_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00700-x","volume":"12","author":"E Berard","year":"2022","unstructured":"Berard E, Rollig C, Bertoli S, Pigneux A, Tavitian S, Kramer M, et al. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer J. 2022;12:107.","journal-title":"Blood Cancer J"},{"key":"1205_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(11)70326-6","volume":"13","author":"M Pfirrmann","year":"2012","unstructured":"Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012;13:207\u201314.","journal-title":"Lancet Oncol"},{"key":"1205_CR52","unstructured":"Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk Stratification in Older Intensively Treated Patients With AML. J Clin Oncol 2024; JCO2302631."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01205-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T12:02:38Z","timestamp":1736596958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01205-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01205-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JS is member of the speaker bureau and advisory board of Jazz Pharmaceuticals, Astellas, Abbvie and Pfizer. JE reports participation in Advisory Boards of Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Amgen and research grants from Novartis, Jazz Pharmaceuticals and Pfizer. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}